Skip to main content

Table 3 Multivariable models showing association between prestroke statins use, NIHSS and Prognosis

From: Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke

 

OR (95% CI)

P*

Model 1 (baseline Ox-LDL)

 Prestroke Statins use

  Mortality

0.38(0.16–0.91)

0.031

  Major disability (mRs3–5)

0.38 (0.15–0.99)

0.047

  Major disability (mRs3–5) + death

0.31(0.17–0.74)

0.009

 NIHSS score

  Mortality

1.18(1.10–1.26)

< 0.001

  Major disability (mRs3–5)

1.17(1.06–1.30)

0.003

  Major disability (mRs3–5) + death

1.20(1.10–1.29)

< 0.001

Model 2(3-month Ox-LDL levels)

 Prestroke Statins use

  Mortality

0.36(1.15–0.87)

0.023

  Major disability (mRs3–5)

0.38(0.15–0.95)

0.038

  Major disability (mRs3–5) + death

0.27(0.11–0.64)

0.003

 NIHSS score

  Mortality

1.18(1.11–1.27)

< 0.001

  Major disability (mRs3–5)

1.17(1.06–1.30)

0.003

  Major disability (mRs3–5) + death

1.19(0.10–1.29)

< 0.001

  1. Bold indicates P-values less than 0.05
  2. *Multivariable adjusted for age, baseline NIHSS score, mean AF duration, CHA2DS2-VASc score, sex, BMI, hypertension, current smoking, current alcohol consumption, diabetes, hyperlipidemia, AF type, family history of stroke, prestroke statins use, baseline Ox-LDL levels (3-month Ox-LDL levels) and use of antihypertensive, warfarin, direct oral anticoagulants, antiplatelets